DEF 14A: AlloVir Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

AlloVir is asking shareholders to approve a reverse stock split to increase its share price and maintain its listing on the Nasdaq Capital Market.

Summary

• AlloVir is holding a special meeting of stockholders on January 9, 2025, to vote on a proposal to authorize a reverse stock split.
• The proposed reverse stock split would combine every 15 to 35 shares of common stock into one share.
• The exact ratio will be determined by the Board of Directors within this range.
• The reverse stock split is intended to increase the company's stock price to meet Nasdaq's minimum bid price requirement for continued listing.
• The company also seeks approval to adjourn the meeting if necessary to solicit additional proxies.
• The record date for the special meeting is December 5, 2024.
• The company intends to mail proxy materials on or about December 6, 2024.
• As of the record date, there were 115,566,991 shares of common stock outstanding.
• The reverse stock split must be implemented before January 10, 2026.

Sentiment

Score: 6

Explanation: The document is primarily factual and procedural, outlining the need for a reverse stock split to maintain Nasdaq listing and facilitate a merger. While the company expresses optimism about the potential benefits, there are also clear risks and uncertainties associated with the action. The sentiment is neutral to slightly positive, reflecting the necessary but potentially risky nature of the proposal.

Positives

• The reverse stock split could make the company's stock more attractive to a broader range of investors.
• A higher stock price could increase institutional investor interest and improve marketability and liquidity.
• The reverse stock split may encourage analysts and brokers to follow or recommend the company.
• The reverse stock split is a condition to the closing of the merger with Kalaris Therapeutics, Inc.

Negatives

• The reverse stock split may not increase the stock price over the long term.
• The reverse stock split may decrease the liquidity of the common stock.
• Some stockholders may end up with odd lots that are more difficult to sell.
• The reverse stock split could lead to a decrease in the company's overall market capitalization.
• The reverse stock split may be viewed negatively by the market.

Risks

• The reverse stock split may not achieve the desired increase in stock price.
• The market price of the common stock may be affected by factors unrelated to the reverse stock split.
• The reverse stock split could lead to reduced trading and a smaller number of market makers.
• The company cannot guarantee that the minimum bid price will remain above the Nasdaq requirement after the reverse stock split.
• The company may not be able to maintain a $4.00 per share minimum bid price for the combined company to be approved for listing on Nasdaq.

Future Outlook

The company intends to file an initial listing application for the combined company to list on The Nasdaq Capital Market and needs to meet a $4.00 per share minimum bid price for a certain number of trading days preceding the closing of the merger. The company will hold a separate special meeting of stockholders to obtain the necessary approvals to complete the merger.

Management Comments

• We believe virtual meetings enable increased stockholder participation from locations around the world.
• Your vote at the Special Meeting is important.
• We appreciate your participation and your interest in AlloVir, Inc.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major stock exchanges due to low share prices. This action is often taken to regain compliance with listing requirements and potentially attract a broader range of investors. The merger with Kalaris Therapeutics is a strategic move to enhance the company's position in the market.

Comparison to Industry Standards

• Many biotechnology companies with low share prices have used reverse stock splits to maintain their Nasdaq listing.
• For example, companies like Agenus Inc. and Ocugen, Inc. have recently implemented reverse stock splits to meet Nasdaq's minimum bid price requirement.
• The range of 1-for-15 to 1-for-35 is within the typical range for reverse stock splits, which can vary widely depending on the company's specific situation and goals.
• The merger with Kalaris is similar to other strategic mergers in the biotech industry, where companies combine to leverage resources and expand their pipelines.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, but their percentage ownership will remain the same, except for fractional shares.
• The reverse stock split may impact the liquidity of the stock, potentially affecting shareholders' ability to trade.
• The reverse stock split is intended to benefit shareholders by maintaining the company's Nasdaq listing and potentially increasing the stock price.
• The merger with Kalaris is intended to create a stronger combined company, which could benefit shareholders in the long term.

Next Steps

• Stockholders need to vote on the reverse stock split proposal.
• The Board will determine the exact reverse stock split ratio if the proposal is approved.
• The company will file the Reverse Stock Split Charter Amendment with the Secretary of State of the State of Delaware if the Board decides to proceed.
• The company will hold a separate special meeting of stockholders to approve the merger with Kalaris Therapeutics, Inc.
• The company will file an initial listing application for the combined company to list on The Nasdaq Capital Market.

Key Dates

Keywords

reverse stock split, Nasdaq, minimum bid price, stockholder meeting, common stock, listing, merger, Kalaris Therapeutics